Vincerx Pharma, Inc.

Vincerx Pharma, Inc. is a U.S.-based clinical-stage biopharmaceutical company built around an exclusive worldwide license to develop bioconjugation and small molecule drug programs. Its business has centered on preclinical and clinical development activities under a Bayer license agreement, with operations conducted primarily in the United States and a small German research presence.

1.21

1.21

— Vincerx Pharma, Inc.
%
Bioconjugation programs0% Licensed drug-development programs focused on bioconjugation-based therapeutics.
Small molecule programs0% Licensed small molecule drug candidates and related development work.
Research and development services100% Preclinical studies, manufacturing development, and clinical/regulatory activities.

Vincerx Pharma does not sell commercial products; its economic counterparties are primarily licensors, research...

  • Research and development vendorsprimary

    CROs, CMOs, laboratories, and consultants that provide preclinical, manufacturing, and regulatory support.

  • Technology licensorprimary

    Bayer, which supplies the licensed patent estate and know-how underlying the programs.

  • Potential pharmaceutical partnerssecondary

    Potential sublicensees or strategic partners that would commercialize programs if advanced.

  • Future healthcare end usersemerging

    Patients and providers who would use approved therapies, though no products are commercialized.

The company has conducted its activities primarily in the United States, while also referencing research activities at...

  • •Primary operating base in the United States
  • •Research activities referenced at a German subsidiary
  • •Worldwide license rights under the Bayer agreement
  • •No disclosed commercial revenue geography because no product sales
  • •Cross-border structure creates U.S. and German compliance exposure

The company’s historical strategy was to advance licensed bioconjugation and small molecule programs through...

01
Wind down operations in an orderly mannershort-term

The company must complete dissolution while satisfying creditors and legal obligations.

02
Retain key personnel and advisorsshort-term

Liquidation requires qualified staff and external providers to complete legal and accounting tasks.

03
Manage licensed IP obligationsshort-term

The Bayer license governs the company’s core development rights and may terminate in dissolution.

The company faces liquidation-specific risks, including uncertainty around residual asset value, claims, reserve...

high

Minimal or no stockholder distribution in dissolution

Residual value depends on liabilities, reserves, asset value, and wind-down costs.

Scope
Stockholders
Materiality
high
high

Inadequate contingency reserve

If reserves are too low, claims could exceed amounts set aside and require clawbacks.

Scope
Liquidation process
Materiality
high
high

License termination under Bayer agreement

The company’s core development rights are tied to a royalty-bearing license.

Scope
Intellectual property
Materiality
high
high

Clinical-stage development and regulatory risk

Drug candidates require successful preclinical, clinical, and regulatory outcomes.

Scope
Pipeline
Materiality
high
medium

Failure to retain qualified personnel

Wind-down requires staff and advisors to complete legal, tax, and SEC obligations.

Scope
Operations
Materiality
medium
Derivative liabilities
Volatility in non-cash expense or income
Accrued expenses and contingency reserves
Residual equity available for distribution
Stock-based compensation
Reported R&D and G&A expense
Grant receivable recoverability
Other income (expense)

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

SCYNEXIS INC

SCYX · Pharmaceutical Preparations

BioCorRx Inc.

BICX · Services-Specialty Outpatient Facilities, NEC

Incannex Healthcare Inc.

IXHL · Pharmaceutical Preparations

REGENEREX PHARMA, INC.

Pharmaceutical Preparations

LENZ Therapeutics, Inc.

LENZ · Biological Products, (No Diagnostic Substances)

: 29.4.2026